These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21766661)

  • 21. Metabolic syndrome: are we at risk?
    Paudel B
    Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome: screening, diagnosis, and management.
    Miller EL; Mitchell A
    J Midwifery Womens Health; 2006; 51(3):141-51. PubMed ID: 16647666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
    Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic implications of growth hormone therapy.
    Perrini S; Carreira MC; Conserva A; Laviola L; Giorgino F
    J Endocrinol Invest; 2008 Sep; 31(9 Suppl):79-84. PubMed ID: 19020393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and treatment of nonalcoholic fatty liver disease.
    Targher G; Bellis A; Fornengo P; Ciaravella F; Pichiri I; Cavallo Perin P; Trimarco B; Marchesini G
    Dig Liver Dis; 2010 May; 42(5):331-40. PubMed ID: 20207207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute heart failure in a patient with metabolic syndrome and diabetes mellitus: clinical evidence for direct positive influence of antidiabetic therapy on left ventricular function.
    Ritzel A; Bell M; Jensen C; Sabin G
    Congest Heart Fail; 2009; 15(3):148-50. PubMed ID: 19522965
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevention and treatment of the metabolic syndrome in the elderly.
    Firdaus M
    J Okla State Med Assoc; 2005 Feb; 98(2):63-6. PubMed ID: 15789643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxisome proliferator-activated receptor gamma: its role in metabolic syndrome.
    Pakala R; Kuchulakanti P; Rha SW; Cheneau E; Baffour R; Waksman R
    Cardiovasc Radiat Med; 2004; 5(2):97-103. PubMed ID: 15464947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
    Towfighi A; Ovbiagele B
    Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The metabolic syndrome].
    Internist (Berl); 1995 May; 36(5 Suppl Metabolisc):1-12. PubMed ID: 9403089
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
    Zhang JL; Zheng X; Zou DJ; Qiu JL; Zhao XX; Qin YW
    Am J Hypertens; 2009 Aug; 22(8):884-90. PubMed ID: 19574961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Basic approach to choose anti-diabetic drugs].
    Hirukawa H; Kaku K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():626-31. PubMed ID: 21766672
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
    Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
    Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk reduction therapy for syndrome X: comparison of several treatments.
    Oron-Herman M; Sela BA; Rosenthal T
    Am J Hypertens; 2005 Mar; 18(3):372-8. PubMed ID: 15797656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit.
    Casteels K; Fieuws S; van Helvoirt M; Verpoorten C; Goemans N; Coudyzer W; Loeckx D; de Zegher F
    Pediatr Diabetes; 2010 Feb; 11(1):61-9. PubMed ID: 19496972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unmet needs in controlling metabolic disease.
    Haffner SM
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome.
    Morgante G; Tosti C; Orvieto R; Musacchio MC; Piomboni P; De Leo V
    Fertil Steril; 2011 May; 95(6):2150-2. PubMed ID: 21194687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity and cardiometabolic syndrome in children.
    Velasquez-Mieyer P; Neira CP; Nieto R; Cowan PA
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):61-81. PubMed ID: 19124396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial.
    Lord J; Thomas R; Fox B; Acharya U; Wilkin T
    BJOG; 2006 Jul; 113(7):817-24. PubMed ID: 16827766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.